Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Q221 Financial Statement Highlights

<< Previous

Bullboard Posts

Next >>

Post by floatinketuckyon Dec 14, 2021 9:18am

661 Views

Post# 34228259

Q221 Financial Statement Highlights

For the 9 months ended September 30th, 2021 Total operating expenses 3,379,146

3,379,146CAD / 9 months = Monthy burn rate CAD 375,460.00 per month.

This is a very low burn rate.

Theralase has backers who exercise warrents when the compnay needs money.
It's been that way for years. That's why they are well into a phase 2 study WITHOUT DEBT.

Quarterly Newsletter 2Q2021.pdf PG 2

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle